USE OF PYRIDOXINE TO INCREASE ANTICACNER ACTIVITY OF METHIONINE-GAMMA-LYASE IN MURINE CANCER MODELS
Autor: | Vadim S. Pokrovsky, Ilya V. Manukhov, Natalya V. Anufrieva, Е. А. Morozova, D. Zh. Davydov, М. V. Komarova, Tatyana V. Demidkina, Е. М. Treshchalina, Gennadii B. Zavilgelsky |
---|---|
Jazyk: | ruština |
Rok vydání: | 2017 |
Předmět: |
Cancer Research
Methionine gamma-lyase business.industry anticancer enzyme Cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens p388 leukemia Pyridoxine medicine.disease mgl lewis lung carcinoma Oncology Biochemistry b16 melanoma medicine methionine-gamma-lyase business l5178y pyridoxine RC254-282 medicine.drug |
Zdroj: | Sibirskij Onkologičeskij Žurnal, Vol 16, Iss 5, Pp 27-35 (2017) |
ISSN: | 2312-3168 1814-4861 |
Popis: | We presented results of monotherapy and combination therapy of transplantable murine tumor models using methionine-gamma-lyase (MGL) and pyridoxine hydrochloride. We studied MGL from Clostridium sporogenes and Citrobacter freundii. We used Lewis lung carcinoma (LLC), melanoma B16, leukemias P388 and L1210 and Fisher lymphadenosis L5178y. Neither monotherapy with MGL nor combination of MGL and pyridoxine demonstrated antitumor activity against P388 and L5178y. In the murine L1210 leukemia model, MGL C. sporogenes injected intraperitoneally in the dose of 2000 U/kg, 11 times with a 12-hour interval increased the life span of mice (ILS=22 %, р=0.035). In the LLC model, the combination of MGL C. sporogenes at a dose of 400 U/kg, i.p., 4 times with a 48-hour interval and pyridoxine at a dose of 250 mg/kg led to tumor growth inhibition (TGI=55 %, р |
Databáze: | OpenAIRE |
Externí odkaz: |